Literature DB >> 12601697

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases.

Martin Kerschensteiner1, Christine Stadelmann, Georg Dechant, Hartmut Wekerle, Reinhard Hohlfeld.   

Abstract

Inflammatory reactions in the central nervous system usually are considered detrimental, but recent evidence suggests that they also can be beneficial and even have neuroprotective effects. Intriguingly, immune cells can produce various neurotrophic factors of various molecular families. The concept of "neuroprotective immunity" will have profound consequences for the pathogenesis and treatment of neuroinflammatory diseases such as multiple sclerosis. It also will prove important for neurodegenerative disorders, in which inflammatory reactions often occur. This review focuses on recent findings that immune cells produce brain-derived neurotrophic factor in multiple sclerosis lesions, whereas neurons and astrocytes express the appropriate tyrosine kinase receptor TrkB. Together with functional evidence for the neuroprotective effects of immune cells, these observations support the concept of "neuroprotective immunity." We next examine current and future therapeutic strategies for multiple sclerosis and experimental autoimmune encephalomyelitis in light of neuroprotective immunity and finally address the broader implications of this new concept for other neuroinflammatory and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601697     DOI: 10.1002/ana.10446

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  57 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials.

Authors:  Frederik Barkhof
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Stem cell transplantation in multiple sclerosis: current status and future prospects.

Authors:  Gianvito Martino; Robin J M Franklin; Anne Baron Van Evercooren; Douglas A Kerr
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

Review 4.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

Review 5.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

6.  Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.

Authors:  Alon Monsonego; Jaime Imitola; Sanja Petrovic; Victor Zota; Anna Nemirovsky; Rona Baron; Yair Fisher; Trevor Owens; Howard L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

Review 7.  Exercise and brain health--implications for multiple sclerosis: Part II--immune factors and stress hormones.

Authors:  Lesley J White; Vanessa Castellano
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

Review 8.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

Review 9.  Rabies.

Authors:  Thiravat Hemachudha; Supaporn Wacharapluesadee; Jiraporn Laothamatas; Henry Wilde
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

Review 10.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.